The scientific expertise, development knowledge and unique patent rights held by DiaGenic make us a leader in identification of gene expression biomarkers in blood. DiaGenic is therefore a valuable partner for pharmaceutical and imaging companies in their drug and product development programs.

Biomarkers can be influential in every phase of drug development, from drug discovery and preclinical evaluations through each phase of clinical trials and into post-marketing studies. Biomarkers can predict a patient’s response to a compound, act as a surrogate endpoint, and aid in making efficacious and cost-saving decisions or terminating drug entities more quickly during the research process. Patient enrichment strategies are using biomarkers to identify certain patient populations that are more likely to respond to the drug therapy or to avoid specific adverse events. This shift toward “personalized medicine,” in which the patient receives a treatment based on their genetic as well as medical profile, is helping the drug industry to achieve the goal of cost-effective and faster research.

The pharma companies therefore state the need for an easy obtainable biomarker and finally an IVD approved diagnostic test, such as a blood test.

The CE marked ADtect® can ensure a homogenous study population in clinical trials for Alzheimer's, thus saving costs and improving success rates. DiaGenic holds a unique library of blood samples and clinical data covering oncology and neurology. Our ongoing projects in developing an MCI progression marker have given access to a unique cohort of well characterized patients and longitudinal samples.

DiaGenic has the expertise and resources to tailor make blood based gene expression biomarkers to support the different phases of drug development.

DiaGenic’s final aim for such collaborations is companion diagnostic products with the use of DiaGenic’s blood based tests together with a new drug or imaging product.